Skip to main content
MarketStoryBook
All storiesLEGN in “The Patent Cliff Sparks a Biotech Land Grab”LEGN in storiesLEGN stock

LEGN in “The Patent Cliff Sparks a Biotech Land Grab”

Legend Biotech Corporation

Bull sideFadingExposure: not rated yet

Legend's successfully commercialized cell therapy and next-generation oncology pipeline make it a proven source of complex biologic assets.

LEGN impact map — “The Patent Cliff Sparks a Biotech Land Grab”

How this story travels from the headline to LEGN’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading LEGN impact map…

Price history, marked with story events

Feb 12, 2024 – Feb 11, 2025 · 251 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

The Patent Cliff Sparks a Biotech Land Grab

Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

BULL side — Legend's successfully commercialized cell therapy and next-generation oncology pipeline make it a proven source of complex biologic assets.

Read the full The Patent Cliff Sparks a Biotech Land Grab story

Bull side

2 stories
  • China Becomes Pharma's Global R&D Engine

    LEGN in “China Becomes Pharma's Global R&D Engine”

    FadingExposure: not rated yet

    Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.

    Legend is a flagship China-origin biotechnology success whose BCMA cell therapy Carvykti became a global product through its partnership with Johnson & Johnson.

  • LEGN in “The Patent Cliff Sparks a Biotech Land Grab”

    FadingExposure: not rated yet
    Viewing

    Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

    Legend's successfully commercialized cell therapy and next-generation oncology pipeline make it a proven source of complex biologic assets.

Bear side

0 stories

No bear-side stories for LEGN yet.